X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: ONL Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
ONL1204 is a novel, Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions. It is being investigated in patients with macula-off rhegmatogenous retinal detachment.
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
Proceeds from the financing will primarily support the advancement of ONL1204 Ophthalmic Solution, a novel, first-in-class small molecule Fas inhibitor, into a Phase 2 clinical trial in patients with macula-off rhegmatogenous retinal detachment (RRD).
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bios Partners
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 08, 2023
Details:
ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
This funding supports the completion of a Phase 1 study in retinal detachment with ONL’s lead compound ONL1204. In addition, the funding will advance ONL1204 in two chronic indications, glaucoma and dry age-related macular degeneration.
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bios Partners
Deal Size: $46.9 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
The FDA-inspected, USA-based Peptide Manufacturer with the Largest Worldwide Capacity.
